• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Ltd ADR (NY: TAK )

    14.32 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Oct 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 14.32
    Bid (Size) 14.05 (4)
    Ask (Size) 14.80 (5)
    Prev. Close 14.32
    Today's Range 14.32 - 14.32
    52wk Range 12.57 - 15.47
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire

    Performance

    YTD
    -0.14%
    -0.14%
    1 Month
    -4.02%
    -4.02%
    3 Month
    +9.23%
    +9.23%
    6 Month
    +5.84%
    +5.84%
    1 Year
    -4.21%
    -4.21%

    More News

    Read More
    Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
    Via Benzinga
    Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
    Via Benzinga
    Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
    Via Benzinga
    Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
    Via Benzinga
    Exposures Product Safety
    New Study Reveals How Classical Music Could Revolutionize Depression Care
    Via PressReach
    Exposures Product Safety
    Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
    Via Benzinga
    Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
    Via InvestorPlace
    Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    3 Biotech Stocks to Buy on the Dip: July 2024
    Via InvestorPlace
    Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
    Via Benzinga
    Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
    Via Benzinga
    Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
    Via Talk Markets
    Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
    Via Benzinga
    Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Takeda Announces New Assignments of Directors
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.